Editor: Atta-ur-Rahman
The eBook series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.
Volume 8 (Atta-ur-Rahman )
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-1-68108-931-7 (Online)
ISBN: 978-1-68108-932-4 (Print)
Volume 7 (Atta-ur-Rahman )
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-1-68108-775-7 (Online)
ISBN: 978-1-68108-776-4 (Print)
Volume 6 (Atta-ur-Rahman )
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-981-14-7843-7 (Online)
ISBN: 978-981-14-7841-3 (Print)
Volume 5 (Atta-ur-Rahman )
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-981-14-0515-0 (Online)
ISBN: 978-981-14-0514-3 (Print)
Volume 4 ( Atta-ur-Rahman)
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-1-68108-481-7 (Online)
ISBN: 978-1-68108-482-4 (Print)
Volume 3 ( Atta-ur-Rahman)
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-1-68108-289-9 (Online)
ISBN: 978-1-68108-290-5 (Print)
This eBook series brings updated reviews to readers interested in research on the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases.
Volume 2 (Atta-ur-Rahman )
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-1-68108-072-7 (Online)
ISBN: 978-1-68108-073-4 (Print)
This eBook series is essential reading for all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the development of anti-cancer agents.
Volume 1 (Atta-ur-Rahman )
ISSN: 2215-0803 (Online)
ISBN: 978-1-60805-798-6 (Online)
ISBN: 978-1-60805-799-3 (Print)
The eBook series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.